A phase I study of NBI-640756 for the treatment of essential tremor.

Trial Profile

A phase I study of NBI-640756 for the treatment of essential tremor.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs NBI 640756 (Primary)
  • Indications Essential tremor
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Aug 2016 According to a Neurocrine Biosciences media release, status changed from active, no longer recruiting to completed.
    • 05 May 2016 According to a Neurocrine Biosciences media release, data from this trial are expected in the second quarter of 2016.
    • 05 May 2016 According to a Neurocrine Biosciences media release, the company has completed dosing in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top